Higher dose imatinib for children with de novo chronic phase chronic myelogenous leukemia: A report from the Children's Oncology Group

Martin A. Champagne, Cecilia H. Fu, Myron Chang, Helen Chen, Robert B. Gerbing, Todd A. Alonzo, Linda D. Cooley, Nyla A. Heerema, Vivian Oehler, Charlotte Wood, Mary Ellen French, Robert J. Arceci, Franklin O. Smith, Mark L. Bernstein

Research output: Contribution to journalArticle

Abstract

Purpose: To determine the efficacy of imatinib in children with newly diagnosed chronic phase (CP) chronic myelogenous leukemia (CML). Methods: This was an open label, multi-center phase II clinical trial. Courses were defined as consecutive 28-day intervals. Oral imatinib was administered daily at 340mg/m2 without interruption in the absence of toxicity. Results: Fifty-one children received 978 28-day courses of imatinib. The most common toxicities encountered were hematologic. Forty-one patients (80%) achieved a complete hematologic response by the end of course 2. Nineteen children (38%) obtained a complete cytogenetic response (CCyR) at the end of course 3. Overall, 72% achieved CCyR at a median time of 5.6 months. The rate of complete molecular response (>3 log reduction) was 27%. Progression-free and overall survival at 3 years were 72%±6.4% and 92%±3.9%, respectively. Conclusions: Daily oral imatinib at a dose of 340mg/m2 is well tolerated in children. In addition, imatinib therapy is effective in inducing a high percent of hematologic, cytogenetic and molecular responses, comparable to adults with CML. (This study was registered at ClinicalTrials.gov under identifier NCT00030394.).

Original languageEnglish (US)
Pages (from-to)56-62
Number of pages7
JournalPediatric Blood and Cancer
Volume57
Issue number1
DOIs
StatePublished - Jul 15 2011

Fingerprint

Leukemia, Myeloid, Chronic Phase
Cytogenetics
Phase II Clinical Trials
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Disease-Free Survival
Imatinib Mesylate

Keywords

  • Imatinib therapy
  • Pediatric chronic myelogenous leukemia

ASJC Scopus subject areas

  • Oncology
  • Pediatrics, Perinatology, and Child Health
  • Hematology

Cite this

Higher dose imatinib for children with de novo chronic phase chronic myelogenous leukemia : A report from the Children's Oncology Group. / Champagne, Martin A.; Fu, Cecilia H.; Chang, Myron; Chen, Helen; Gerbing, Robert B.; Alonzo, Todd A.; Cooley, Linda D.; Heerema, Nyla A.; Oehler, Vivian; Wood, Charlotte; French, Mary Ellen; Arceci, Robert J.; Smith, Franklin O.; Bernstein, Mark L.

In: Pediatric Blood and Cancer, Vol. 57, No. 1, 15.07.2011, p. 56-62.

Research output: Contribution to journalArticle

Champagne, MA, Fu, CH, Chang, M, Chen, H, Gerbing, RB, Alonzo, TA, Cooley, LD, Heerema, NA, Oehler, V, Wood, C, French, ME, Arceci, RJ, Smith, FO & Bernstein, ML 2011, 'Higher dose imatinib for children with de novo chronic phase chronic myelogenous leukemia: A report from the Children's Oncology Group', Pediatric Blood and Cancer, vol. 57, no. 1, pp. 56-62. https://doi.org/10.1002/pbc.23031
Champagne, Martin A. ; Fu, Cecilia H. ; Chang, Myron ; Chen, Helen ; Gerbing, Robert B. ; Alonzo, Todd A. ; Cooley, Linda D. ; Heerema, Nyla A. ; Oehler, Vivian ; Wood, Charlotte ; French, Mary Ellen ; Arceci, Robert J. ; Smith, Franklin O. ; Bernstein, Mark L. / Higher dose imatinib for children with de novo chronic phase chronic myelogenous leukemia : A report from the Children's Oncology Group. In: Pediatric Blood and Cancer. 2011 ; Vol. 57, No. 1. pp. 56-62.
@article{d23cf56e2f6a477f9888b9276e80ec6d,
title = "Higher dose imatinib for children with de novo chronic phase chronic myelogenous leukemia: A report from the Children's Oncology Group",
abstract = "Purpose: To determine the efficacy of imatinib in children with newly diagnosed chronic phase (CP) chronic myelogenous leukemia (CML). Methods: This was an open label, multi-center phase II clinical trial. Courses were defined as consecutive 28-day intervals. Oral imatinib was administered daily at 340mg/m2 without interruption in the absence of toxicity. Results: Fifty-one children received 978 28-day courses of imatinib. The most common toxicities encountered were hematologic. Forty-one patients (80{\%}) achieved a complete hematologic response by the end of course 2. Nineteen children (38{\%}) obtained a complete cytogenetic response (CCyR) at the end of course 3. Overall, 72{\%} achieved CCyR at a median time of 5.6 months. The rate of complete molecular response (>3 log reduction) was 27{\%}. Progression-free and overall survival at 3 years were 72{\%}±6.4{\%} and 92{\%}±3.9{\%}, respectively. Conclusions: Daily oral imatinib at a dose of 340mg/m2 is well tolerated in children. In addition, imatinib therapy is effective in inducing a high percent of hematologic, cytogenetic and molecular responses, comparable to adults with CML. (This study was registered at ClinicalTrials.gov under identifier NCT00030394.).",
keywords = "Imatinib therapy, Pediatric chronic myelogenous leukemia",
author = "Champagne, {Martin A.} and Fu, {Cecilia H.} and Myron Chang and Helen Chen and Gerbing, {Robert B.} and Alonzo, {Todd A.} and Cooley, {Linda D.} and Heerema, {Nyla A.} and Vivian Oehler and Charlotte Wood and French, {Mary Ellen} and Arceci, {Robert J.} and Smith, {Franklin O.} and Bernstein, {Mark L.}",
year = "2011",
month = "7",
day = "15",
doi = "10.1002/pbc.23031",
language = "English (US)",
volume = "57",
pages = "56--62",
journal = "Pediatric Blood and Cancer",
issn = "1545-5009",
publisher = "Wiley-Liss Inc.",
number = "1",

}

TY - JOUR

T1 - Higher dose imatinib for children with de novo chronic phase chronic myelogenous leukemia

T2 - A report from the Children's Oncology Group

AU - Champagne, Martin A.

AU - Fu, Cecilia H.

AU - Chang, Myron

AU - Chen, Helen

AU - Gerbing, Robert B.

AU - Alonzo, Todd A.

AU - Cooley, Linda D.

AU - Heerema, Nyla A.

AU - Oehler, Vivian

AU - Wood, Charlotte

AU - French, Mary Ellen

AU - Arceci, Robert J.

AU - Smith, Franklin O.

AU - Bernstein, Mark L.

PY - 2011/7/15

Y1 - 2011/7/15

N2 - Purpose: To determine the efficacy of imatinib in children with newly diagnosed chronic phase (CP) chronic myelogenous leukemia (CML). Methods: This was an open label, multi-center phase II clinical trial. Courses were defined as consecutive 28-day intervals. Oral imatinib was administered daily at 340mg/m2 without interruption in the absence of toxicity. Results: Fifty-one children received 978 28-day courses of imatinib. The most common toxicities encountered were hematologic. Forty-one patients (80%) achieved a complete hematologic response by the end of course 2. Nineteen children (38%) obtained a complete cytogenetic response (CCyR) at the end of course 3. Overall, 72% achieved CCyR at a median time of 5.6 months. The rate of complete molecular response (>3 log reduction) was 27%. Progression-free and overall survival at 3 years were 72%±6.4% and 92%±3.9%, respectively. Conclusions: Daily oral imatinib at a dose of 340mg/m2 is well tolerated in children. In addition, imatinib therapy is effective in inducing a high percent of hematologic, cytogenetic and molecular responses, comparable to adults with CML. (This study was registered at ClinicalTrials.gov under identifier NCT00030394.).

AB - Purpose: To determine the efficacy of imatinib in children with newly diagnosed chronic phase (CP) chronic myelogenous leukemia (CML). Methods: This was an open label, multi-center phase II clinical trial. Courses were defined as consecutive 28-day intervals. Oral imatinib was administered daily at 340mg/m2 without interruption in the absence of toxicity. Results: Fifty-one children received 978 28-day courses of imatinib. The most common toxicities encountered were hematologic. Forty-one patients (80%) achieved a complete hematologic response by the end of course 2. Nineteen children (38%) obtained a complete cytogenetic response (CCyR) at the end of course 3. Overall, 72% achieved CCyR at a median time of 5.6 months. The rate of complete molecular response (>3 log reduction) was 27%. Progression-free and overall survival at 3 years were 72%±6.4% and 92%±3.9%, respectively. Conclusions: Daily oral imatinib at a dose of 340mg/m2 is well tolerated in children. In addition, imatinib therapy is effective in inducing a high percent of hematologic, cytogenetic and molecular responses, comparable to adults with CML. (This study was registered at ClinicalTrials.gov under identifier NCT00030394.).

KW - Imatinib therapy

KW - Pediatric chronic myelogenous leukemia

UR - http://www.scopus.com/inward/record.url?scp=79955733477&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79955733477&partnerID=8YFLogxK

U2 - 10.1002/pbc.23031

DO - 10.1002/pbc.23031

M3 - Article

C2 - 21465636

AN - SCOPUS:79955733477

VL - 57

SP - 56

EP - 62

JO - Pediatric Blood and Cancer

JF - Pediatric Blood and Cancer

SN - 1545-5009

IS - 1

ER -